Pharvaris N.V.

NasdaqGS:PHVS 주식 리포트

시가총액: US$2.1b

Pharvaris 대차대조표 건전성

재무 건전성 기준 점검 6/6

Pharvaris 의 총 주주 지분은 €236.3M 이고 총 부채는 €0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 €259.8M 및 €23.5M 입니다.

핵심 정보

0%

부채/자본 비율

€0

부채

이자보상배율n/a
현금€246.96m
자본€236.33m
총부채€23.46m
총자산€259.79m

최근 재무 건전성 업데이트

분석 기사 • Jul 05

Here's Why We're Watching Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Mar 17

We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Dec 02

Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Aug 16

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • Oct 09

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Pharvaris ( NASDAQ:PHVS...
분석 기사 • May 13

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Recent updates

Seeking Alpha • Nov 23

Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating

Summary I initiate Pharvaris with a buy rating and $40 target price, driven by its differentiated oral bradykinin B2 antagonist franchise for HAE. PHVS's late-stage pipeline targets both on-demand and prophylactic HAE treatment, with pivotal phase 3 data expected by year-end 2025. Deucrictibant's validated mechanism, strong phase 2 results, and regulatory precedent de-risk the upcoming phase 3 readout, supporting a high probability of success of 90%+ (author's judgement). Key risks include clinical, commercial, and financing uncertainties, but the risk-reward profile remains attractive ahead of multiple catalysts. Read the full article on Seeking Alpha
분석 기사 • Jul 05

Here's Why We're Watching Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Mar 17

We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 29

Pharvaris: Despite 30% Decline, Still Fair At Best

Summary Pharvaris is a pre-revenue biotech company with significant cash burn and a high development burden, making it a risky investment in a high-cost capital environment. Despite positive trial data, the company's valuation remains optimistic, considering the market size and potential outstanding development costs. The current market cap of $1 billion + $900 million development burden against a $2 billion gross value capture is not a great value setup. With only $300 million in liquidity and an estimated $900 million development burden, Pharvaris also has reflexivity risks. Read the full article on Seeking Alpha
분석 기사 • Dec 02

Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Aug 16

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jan 17

Pharvaris: Digging Deep For Sufficient Market Size

Summary Pharvaris is developing a molecule called Deucrictibant to treat acute hereditary angioedema (HAE) and provide prophylactic treatment. The market size for HAE is estimated to be around $2 billion, but that's digging deep and outside of the more profitable developed markets. Pharvaris has $440 million in available liquidity, including cash and a newly underwritten issue, but there is still a significant R&D burden and potential dilution in the company's future. At a $1.45 billion market cap, with outstanding burdens and a best-case market size at $2 billion according to our figures, we don't see the appeal here. Read the full article on Seeking Alpha
분석 기사 • Oct 09

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Pharvaris ( NASDAQ:PHVS...
분석 기사 • May 13

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
분석 기사 • Jan 11

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Sep 26

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 12

Pharvaris GAAP EPS of -€0.38

Pharvaris press release (NASDAQ:PHVS): Q2 GAAP EPS of -€0.38. Cash and cash equivalents were €201 million as of June 30, 2022, compared to €209 million as of December 31, 2021.
Seeking Alpha • Aug 22

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Pharvaris N.V. (NASDAQ:PHVS) dropped ~19% in the pre-market trading Monday after the Dutch biopharma announced that the FDA verbally notified its plans to issue a clinical hold on the clinical trials of hereditary angioedema candidate PHA121. The decision is based on a review of nonclinical data, and the agency intends to offer a formal clinical hold letter within the next 30 days. A small molecule bradykinin B2-receptor antagonist, PHA121, was undergoing clinical studies in the U.S. under two Investigational New Drug (IND) applications for HAE. “We are fully committed to working closely with the FDA to address the agency’s concerns,” PHVS Chief Executive Berndt Modig remarked.
분석 기사 • Jun 08

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Dec 21

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Aug 25

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

재무 상태 분석

단기부채: PHVS 의 단기 자산 ( €257.7M )이 단기 부채( €22.9M ).

장기 부채: PHVS의 단기 자산(€257.7M)이 장기 부채(€532.6K)를 초과합니다.

부채/자본 비율 추이 및 분석

부채 수준: PHVS 부채가 없습니다.

부채 감소: PHVS는 지난 5년 동안 부채가 전혀 없었습니다.

대차대조표

현금 보유 기간 분석

과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.

안정적인 현금 활주로: PHVS 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: PHVS 29.5 1.4 29.5 % 매년.

건전한 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/06/01 20:29
종가2026/06/01 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Pharvaris N.V.는 17명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Tazeen AhmadBofA Global Research
Steven SeedhouseCantor Fitzgerald & Co.
Jonathan WollebenCitizens JMP Securities, LLC